Joseph E. Sokal, M.D., F.A.C.P.; C. W. Aungst, M.D., F.A.C.P.; James T. Grace Jr., M.D.
This content is PDF only. Please click on the PDF icon to access.
Death from chronic myelocytic leukemia usually results from myeloblastic transformation. In 1965, efforts were initiated to prevent or delay such death by immunizing patients with cultured cells established from blood of  a patient with acute myeloblastic leukemia (earlier vaccinations) and  a patient in blastic crisis of Ph′-positive chronic myelocytic leukemia (from 1970). Cells are mixed with BCG organisms as adjuvant, and injected intradermally. All patients continue on antileukemic chemotherapy. Of 21 patients who have received three or more vaccinations, 16 developed delayed hypersensitivity to the target cells, and 15 exhibited a general increase in cellular immune reactivity. The
Sokal JE, Aungst CW, Grace JT. Immunotherapy of Myeloid Leukemia.. Ann Intern Med. ;76:878. doi: 10.7326/0003-4819-76-5-878_1
Download citation file:
Published: Ann Intern Med. 1972;76(5):878.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use